Parkon® in the treatment of multiple sclerosis. A pilot study

<p>Multiple Sclerosis (MS) is one of the most common chronic demyelinating diseases of the central nervous system. The disease affects and relatively quickly leads to disability in mainly people 15-40 years of age. The development of MS can occur progressively or with exacerbations and remissi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Goldstein NI (Egilea), Golubev VL (Egilea), Goldstein RN (Egilea)
Formatua: Liburua
Argitaratua: Open Journal of Parkinson's Disease and Treatment - Peertechz Publications, 2020-08-07.
Gaiak:
Sarrera elektronikoa:Connect to this object online.
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak